1. The extractions of glucose, lactate, pyruvate and free fatty acids by dog heart in vivo were calculated from measurements of their arterial and coronary sinus blood concentration. Elevation of plasma free fatty acid concentrations by infusion of intralipid and heparin resulted in increased extraction of free fatty acids and diminished extractions of glucose, lactate and pyruvate by the heart. It is suggested that metabolism of free fatty acids by the heart in vivo, as in vitro, may impair utilization of these substrates. These effects of elevated plasma free fatty acid concentrations on extractions by the heart in vivo were reversed by injection of dichloroacetate, which also improved extraction of lactate and pyruvate by the heart in vivo in alloxan diabetes. 2. Sodium dichloroacetate increased glucose oxidation and pyruvate oxidation in hearts from fed normal or alloxandiabetic rats perfused with glucose and insulin. Dichloroacetate inhibited oxidation of acetate and 3-hydroxybutyrate and partially reversed inhibitory effects of these substrates on the oxidation of glucose. In rat diaphragm muscle dichloroacetate inhibited oxidation of acetate, 3-hydroxybutyrate and palmitate and increased glucose oxidation and pyruvate oxidation in diaphragms from alloxan-diabetic rats. Dichloroacetate increased the rate of glycolysis in hearts perfused with glucose, insulin and acetate and evidence is given that this results from a lowering of the citrate concentration within the cell, with a consequent activation of phosphofructokinase. 3. In hearts from normal rats perfused with glucose and insulin, dichloroacetate increased cell concentrations of acetyl-CoA, acetylcarnitine and glutamate and lowered those of aspartate and malate. In perfusions with glucose, insulin and acetate, dichloroacetate lowered the cell citrate concentration without lowering the acetyl-CoA or acetylcamitine concentrations. Measurements of specific radioactivities of acetyl-CoA, acetylcarnitine and citrate in perfusions with [1-14C]acetate indicated that dichloroacetate lowered the specific radioactivity of these substrates in the perfused heart. Evidence is given that dichloroacetate may not be metabolized by the heart to dichloroacetyl-CoA or dichloroacetylcarnitine or citrate or CO2. 4. We suggest that dichloroacetate may activate pyruvate dehydrogenase, thus increasing the oxidation of pyruvate to acetyl-CoA and acetylcarnitine and the conversion of acetyl-CoA into glutamate, with consumption of aspartate and malate. Possible mechanisms for the changes in cell citrate concentration and for inhibitory effects of dichloroacetate on the oxidation of acetate, 3-hydroxybutyrate and palmitate are discussed.
1. The extractions of glucose, lactate, pyruvate and free fatty acids by dog heart in vivo were calculated from measurements of their arterial and coronary sinus blood concentration. Elevation of plasma free fatty acid concentrations by infusion of intralipid and heparin resulted in increased extraction of free fatty acids and diminished extractions of glucose, lactate and pyruvate by the heart. It is suggested that metabolism of free fatty acids by the heart in vivo, as in vitro, may impair utilization of these substrates. These effects of elevated plasma free fatty acid concentrations on extractions by the heart in vivo were reversed by injection of dichloroacetate, which also improved extraction of lactate and pyruvate by the heart in vivo in alloxan diabetes. 2. Sodium dichloroacetate increased glucose oxidation and pyruvate oxidation in hearts from fed normal or alloxandiabetic rats perfused with glucose and insulin. Dichloroacetate inhibited oxidation of acetate and 3-hydroxybutyrate and partially reversed inhibitory effects of these substrates on the oxidation of glucose. In rat diaphragm muscle dichloroacetate inhibited oxidation of acetate, 3-hydroxybutyrate and palmitate and increased glucose oxidation and pyruvate oxidation in diaphragms from alloxan-diabetic rats. Dichloroacetate increased the rate of glycolysis in hearts perfused with glucose, insulin and acetate and evidence is given that this results from a lowering of the citrate concentration within the cell, with a consequent activation of phosphofructokinase. 3. In hearts from normal rats perfused with glucose and insulin, dichloroacetate increased cell concentrations of acetyl-CoA, acetylcarnitine and glutamate and lowered those of aspartate and malate. In perfusions with glucose, insulin and acetate, dichloroacetate lowered the cell citrate concentration without lowering the acetyl-CoA or acetylcamitine concentrations. Measurements of specific radioactivities of acetyl-CoA, acetylcarnitine and citrate in perfusions with [1-14C] acetate indicated that dichloroacetate lowered the specific radioactivity of these substrates in the perfused heart. Evidence is given that dichloroacetate may not be metabolized by the heart to dichloroacetyl-CoA or dichloroacetylcarnitine or citrate or CO2. 4. We suggest that dichloroacetate may activate pyruvate dehydrogenase, thus increasing the oxidation of pyruvate to acetyl-CoA and acetylcarnitine and the conversion of acetyl-CoA into glutamate, with consumption of aspartate and malate. Possible mechanisms for the changes in cell citrate concentration and for inhibitory effects of dichloroacetate on the oxidation of acetate, 3-hydroxybutyrate and palmitate are discussed.
The reactions catalysed by hexokinase (EC 2.7.1.1), phosphofructokinase (EC 2.7.1.11) and pyruvate dehydrogenase (EC 1.2.4.1) are inhibited in the perfused rat heart by the oxidation of short-and longchain fatty acids, chylomicron fatty acids, and ketone bodies (Williamson, 1964; Randle et al., 1966; Ontko & Randle, 1967) and by alloxan diabetes (Park et al., 1961; Randle et al., 1966) . The mechanisms may involve inhibition of phosphofructokinase hearts 2-bromo fatty acids inhibit palmitate oxidation, and reactivation of the hexokinase, phosphofructokinase and pyruvate dehydrogenase reactions has been shown in alloxan diabetes (Burges et al., 1968; Randle, 1969) . These inhibitors are, however, inconvenient to use because rigid control of concentration and time of exposure are necessary if other less-specific effects (e.g. interference with ATP synthesis and cessation of muscular contraction) are to be avoided. Lorini & Ciman (1962) found that di-isopropylammonium dichloroacetate raises the respiratory quotient in alloxan-diabetic rats. This observation suggested that the compound may promote glucose oxidation and inhibit fatty acid oxidation and thus be a useful metabolic inhibitor. Preliminary experiments showed that sodium dichloroacetate stimulates oxidation of glucose in vitro by heart or diaphragm muscle from alloxan-diabetic rats (McAllister & Randle, 1970) . Stacpoole & Felts (1970 , in their studies of the effects of dichloroacetate on glucose oxidation in diabetic muscle, suggested that the compound may act by inhibiting the oxidation of long-chain fatty acids. Our own studies have suggested that other mechanisms may be involved and we describe here effects of dichloroacetate in vitro on the metabolism of glucose, pyruvate, acetate, 3-hydroxybutyrate and palmitate and on concentrations of metabolites in rat heart and diaphragm muscles, and on the extractions of glucose, lactate, pyruvate and free fatty acids by dog heart in vivo.
Materials
Enzymes (1953) . Acetyl-L-camitine was synthesized by the method of Fraenkel & Friedman (1957) . Dichloroacetyl-L-carnitine was synthesized by a similar method; excess of dichloroacetyl chloride was removed by rotary evaporation and dichloroacetic acid was removed by passage through a column of Dowex 1 resin (formate form) and elution of dichloroacetylcarnitine with water, followed by concentration by freeze-drying. Dichloroacetylcarnitine was assayed as L-carnitine after saponification in 5M-KOH for 45min at 70°C. L-Carnitine was assayed spectrophotometrically as CoA released from acetylCoA by carnitine acetyltransferase by using 5,5'-dithiobis(nitrobenzoic acid) and dichloroacetate was identified by t.l.c. (see below). The product contained equimolar amounts of L-carnitine and dichloroacetyl-L-carnitine and was not further purified. Dichloro-[1-14C]acetic acid was synthesized by copper reduction of trichlorol-14C]acetic acid in aqueous solution (Doughty & Derge, 1931) . After removal of copper as CuS with H2S, dichloroacetate was crystallized as the benzyl thiuronium salt and converted into dichloroacetic acid with Permutit Zeo-Karb cationexchanger (H+ form). The purity of benzyl thiuronium dichloroacetate was checked by melting point (173-175°C; stated 178°C) and by t.l.c. on silica-gel G plates in butan-2-one containing 0.25 % (v/v) formic acid, and detected by spraying with 0.1 % (w/v) Bromophenol Blueinethanol. Dichloroacetic acid and trichloroacetic acid were located by markers and radioactivity was assayed by liquid-scintillation spectrometry after the spot had been scraped from the plate. By this method dichloro[14C]acetic acid preparations contained less than 1 % of trichloro-
[14C]acetic acid.
Methods
Heart and diaphragm experiments Heart perfusions. Hearts were from male albino Wistar rats (250-400g) with free access to diet 41B (Oxoid Ltd., London E.C.4, U.K.). Rats were injected with heparin and Nembutal intraperitoneally before excision of the heart. The perfusion medium was bicarbonate-buffered salt solution (Krebs & Henseleit, 1932) modified by decreasing the concentration ofCaCl2 to one-halfand by adding 0.6mM-EDTA (calcium salt). This medium was gassed with 02+C02 (95:5) and contained glucose (5.5mM) and insulin (0.01 i.u./ml) with other additions given in the text, figures or tables.
Hearts were perfused at 38°C by drip-through by a cannula inserted in the aorta; the perfusion pressure was 60mmHg (6.7kPa Tissue extracts. For metabolite assays and measurements of specific radioactivities, hearts were rapidly frozen with a tissue clamp at the temperature of liquid N2 and trimmed of fat. Hemidiaphragms were frozen in liquid N2. Tissues were powdered in a percussion mortar at -70°C and a weighed amount of powder was extracted at 0°C with 5% (w/v) HC104 (approx. 2.5ml/g of powder) and centrifuged at 0°C. A measured volume of supernatant was neutralized at 0°C with saturated KHCO3 and the KC104 removed by centrifugation at the same temperature. For assay of adenine nucleotides extracts were made at -10 to -15°C in 5 % (w/v) HC104 in 15 % (w/v) acetone and assayed within 24h.
Determinations
Glucose, lactate and pyruvate in the medium. Glucose was assayed spectrophotometrically (Slein, 1963) . Lactate and pyruvate were assayed (after deproteinization with HC104) spectrophotometrically or fluorimetrically by the methods of Hohorst (1963) and Bucher et al. (1963) .
Metabolites in heart and diaphragm. These were assayed spectrophotometrically or fluorimetrically by methods listed by Neely et al. (1972) ; additionally acetyl-L-carnitine was assayed by the method of Pearson & Tubbs (1967) .
Oxygen. Concentrations of 02 were measured in the perfusion medium at 37°C with a Clark 02 electrode calibrated with medium saturated with 02 +C02 (95: 5) at 37°C and with medium freed of 02 with dithionite. Glycolysis rate. Glycolysis rate in perfused heart was measured from the production of 3H20 from [5-3H] glucose (Neely et al., 1972) .
Radioactivity. This was assayed in a NuclearChicago mark I liquid-scintillation spectrometer with either toluene or methoxyethanol-toluene (2:3, v/v) containing butyl-PBD [5-(4-biphenylyl)-2-(4-t-butylphenyl)-l-oxa-3,4-diazole] and naphthalene. Quenching corrections were determined by the channels-ratio method by an external standard.
Incorporations of radioactivity from 14C-labelled compounds into CO2 in heart and diaphragm were measured by methods given by . Specific radioactivities of acetyl-CoA and citrate (acetate and oxaloacetate moieties) were measured by ion-exchange chromatography and enzymic conversions as described by Randle et al. (1970) . For measurement of the specific radioactivitiy of acetyl-Lcarnitine this substance was assayed in heart extracts. Carrier acetyl-L-carnitine was then added and the concentration assayed again to give the dilution factor. Acetyl-L-carnitine was then purified for assay of radioactivity by applying a measured volume of extract to a column (20cm x 1 cm) Group 2. These experiments were designed to investigate effects of intralipid plus heparin with and without dichloroacetate. In seven dogs 0.9% NaCl was infused over the first 1.5h and blood samples were taken at 1, 1.25 and 1.5h. Heparin was then injected intravenously (1000 units) and a constant infusion of intralipid (40ml/h) and heparin (400 units/ h) given from 1.5 to 3 h; blood samples were taken at 2.5, 2.75 and 3h. In three of the dogs a single dose of sodium dichloroacetate (3g) was administered at the end of 3h and intralipid and heparin infusions were continued for a further 60min; blood samples were taken at 5, 10, 20, 30, 45 and 60min after the injection of dichloroacetate.
Group 3. In these experiments two dogs were rendered diabetic by intravenous injection of alloxan (70mg/kg) and used after 48h. Infusion of0.9 % NaCl was made and blood samples were taken at 1, 1.25 and 1.5h. Sodium dichloroacetate (3g) was then given intravenously and further blood samples were taken at 5, 10, 20, 30, 45 and 60min. Blood samples. Blood samples were collected in heparinized syringes and placed in centrifuge tubes at 0°C. For assay of glucose, lactate and pyruvate whole blood was deproteinized within 5min of collection with 0.6M-perchloric acid; the extracts obtained by centrifuging were neutralized with saturated KHCO3. Samples of plasma for estimation of free fatty acids were rapidly separated by using a refrigerated centrifuge and the fatty acids extracted by using a modification of the method of Dole (Trout et 
R&esu1ts
Effects of elevated plama free fatty acids and of dichloroacetate on extraetions of glucose, lactate, pyruvate andfree fatty acids by dog heart ift vivo Table 1 shows the results of control experiments in five dogs to establish the existence of steady-state concentrations and arteriovenous differences across the heart during 3 h of infusion with 0.9% NaCl. The experimental design involved measurements on blood samples taken at 1, 1.25 and 1.5h (period 1) and at 2.5, 2.75 and 3 h (period 2). There were no significant differences between the mean values in each of the two periods for arterial blood concentrations of glucose, lactate or pyruvate or plasma concentrations of free fatty acids or for arteriovenous concentration differencs for these substances. Table 2 shows the results of experiments in seven dogs in which the experimental design was varied by a single injection of heparin at the beginning of period 2 and infusion of intralipid and heparin in place of 0.9% NaCl in period 2. Elevation ofplasma free fatty acids by intralipid and heparin in the second period had no effect on arterial blood concentrations of glucose, lactate or pyruvate. As shown by the arteriovaenous differences, the myocardial extractions of glucose, lactate and pyruvate were inhibited 60-85% at the higher concentration of free fatty acids. Table 3 shows the results of experiments similar to those shown in Table 2 , but with the addition of a third period in which measurements were continued for a further hour after the injection of a single dose of sodium dichloroacetate (4g). As in The experimental conditions and times of sampling during periods 1 and 2 were as in Table 2 . In these experiments initusion of intralipid was continued for a third perlod of 1 h at the saffie rate as in period 2. A single in-jecti6o of sodium dichloroacetate (4g) was given intravenously at the beginning of period 3 and further samples were taken after 5, 10i 20, 30, 45 so marked that none could be detected in plasma of blood taken from the coronary sinus after injection of dichloroacetate (lower limit of assay approx. 10% of pyruvate concentration before dichloroacetate injection). The concentration of plasma free fatty acids and the extraction of free fatty acids by the heart did not change significantly with dichloroacetate. As shown in Fig. 1 the action of dichloroacetate was rapid, increased extractions of lactate and pyruvate being detected within 5min. Fig. 2 shows the effect of a single injection of dichloroacetate (4g) in two alloxan-diabetic dogs (blood glucose concentrations 360mg/100ml in the unfed state). The arterial concentration of glucose and the arteriovenous concentration differences for glucose showed no consistent change with dichloroacetate (not shown). (Table 6 ). 17.3*± 1.1" (4) 44.0± 1.4** (14) 20.0± 1.6** (5) 127.9± 5,2** (5) (Table 10) . By visual inspection dichloroacetate had no effect on either the rate or the force of cardiac contraction in the perfused rat heart.
Effects of dichloroacetate on concentrations of nwtabolites in perfused rat heart
In glucoe Perfusiongdichloroacetate (at 10mm, as shown, ot at 1 mnm not shown) markedly incteased the concentrations of acetylCoA and acetylcarnitine in hearts from normal rats. Cohcentration of glutamate was also increaged and those of pyruvate, aspartate and malate dereased, suggesting increased oxidation ofpyruvate into acetyl-CoA and increased incorporation of acetyl-CoA into glutamate, with the oxaloacetate required being derived from aspartate (by transahination with 2-oxoglutarate) and malate.
Concentratiobs of citratei glucose 6&phosphate arid adenine nucleotides were urnchanged (Table 9) . Acetate perfusioii led to the expected changes in mettibolite concentrations: increases in acetyl-CoA and acetylcarnitind; increases in citrate and glutamate with provision of oxaloacetate through a decrease ini aspartate; an increasb in glucose 6-phosphate as a result of inhibition of phosphofructokinase and glycolysis by citrate (Table 9 ; Williamson, 1965; Bowman, 1966; Randle et al., 1970) . In acetate perfusions, dichloroacetate lowered heart ditrate co0nentration and this was associated with accelerated glycolysis and lowered glucose 6-phosphate concentration, indicating activation of phosphofructokinase (Tables 8 and 9 ). The concentrations of acetyl-CoA, acetylcatnitine, glutamate, aspartate and adenine nucleotides were not significantly altered by dichloroacetate in acetate perfusionis (Table 9) . Dichloroacetate also lowered concentrations of citrate and glucose 6-phosphate during perfusion with DL-3-hydroxybutyrate.
In diaphragms from normal rats incubated with 1973 Effects ofdichloroacetate on the specific radioactivities ofacetyl-CoA, acetylcarnitine and citrate in rat heart Scheme 1 shows a model capable of accounting for the effects of dichloroacetate on the concentraVol. 134 tions of acetyl-CoA and citrate. The model postulates two compartments of CoA and carnitine in rat heart mitochondria. The small compartment contains pyruvate dehydrogenase, citrate synthase and carnitine acetyltransferase and can form acetyl-CoA, acetylcarnitine and citrate. The large compartment can form acetyl-CoA and acetylcarnitine from acetate, palmitate and ketone bodies, but not from pyruvate; it lacks citrate synthase. It is postulated that the two pools of acetyl-CoA and acetylcarnitine are equilibrated through an 'acetyltransferase'. Citrate synthesis from acetate would involve synthesis of acetylCoA in the large compartment, acetyl transfer to form acetyl-CoA in the small compartment, followed by citrate synthesis in the small compartment. The model postulates inhibition of the 'acetyltransferase' by dichloroacetate. In perfusions with glucose, acetate and dichloroacetate, acetyl-CoA is synthesized in the large compartment but acetyl transfer into the small compartment for synthesis of citrate is inhibited; citrate is thus synthesized from acetylCoA formed by the oxidation of pyruvate in the small compartment. The concentration ofacetyl-CoA in the large compartment would thus be high because of synthesis from acetate. The concentration in thp small compartment would remain low and hence citrate concentration would be low. In perfusions with glucose, dichloroacetate inhibits transfer of acetyl groups between the two compartments. AcetylCoA in the small compartment is formed from pyruvate and metabolized through citrate. Acetyl-CoA is synthesized at a slow rate in the large compartment from palmitate formed by the breakdowVn of endogenous triglyceride and accumulates, thus leading to an elevated concentration of tissue acetyl-CoA. The idea of two pools of acetyl-CoA has also been postulated for rat heart mitQchondria by Pearson & Tubbs (1967) to account for metabolic effects of propionate, and by Fritz (1967 Reactions (2) and (3) in Scheme 2 were tested by incubation of dichloroacetyl-L-carnitine (0.5,tmol) with CoA, malate, NAD+, carnitine acetyltransferase and citrate synthase under conditions described for the assay of acetyl-L-carnitine by Pearson & Tubbs (1967) . If reactions (2) and (3) This observation appears to preclude reactions (2) and (3) and also shows that dichloroacetyl-L-carnitine is not an inhibitor of carnitine acetyltransferase.
This o-.ervation does not preclude reaction (2) alone or reaction (3) alone. Attempts to prepare dichlorogwetyl-foA !y chenrcal nethods for acetyl-CoA (Simon & Shemin, 1953) were unsuccessful. Attempts to prepare dichloroacetyl-CoA or to demonstrate formation of dichloroacetyl-CoA by reactio,n (1) of the scheme with ox heart acetyl-CoA synthetase were also unsuccessful. step at the end and approx. 75 % of the applied radioactivity (0.1 uCi) was eluted by this step from applied dichloroacetate or perchloric acid extract of heart. The water wash (which would be expected to contain dichloroacetylcarnitine) yielded 0.15% of the radioactivity from dichloroacetate columns and 0.14-0.5 % from columns with heart extracts. The remaining fractions (formic acid gradient, ammnonium formate gradient, ammonium formate step) yielded 2% of the radioactivity applied in dichloroacetate and 1.2-3% of the radioactivity applied in heart extracts. The water wash from the Dowex 1 (formate form) column to which was applied heart extract perfused by thfe human heart in vivo. Chylopicrop fatty acids can also inhibit uptake and oxidation of glucose by rat heart in vitro (Ontko Randle, 1967 Metabolism of acetate in rat heart increases tissue concentrations of acetyl-CoA, acetylcarnitine, citrate and glutamate and lowers that of aspartate . If dichloroacetate improves glucose oxidation in acetate perfusions by inhibiting acetate oxidation then it might be expected to reverse the effects of acetate on tissue-metabolite concentrations. Although dichloroacetate lowered citrate concentration it did not lower tissue acetyl-CoA and acetylcarnitine concentrations. Moreover, measurements of specific radioactivities in perfusions with [1-14C1-acetate indicated that a substantial proportion of the accumulated acetylhCoA was derived from a nonradioactive precursor (presumably pyruvate) in perfusion with dichloroacetate. This suggested that dichloroacetate may directly increase pyruvate oxidation. The observation that dichloroacetate inpreased tissue concentrations of acetyl-CoA and acetylcarnitine and lowered that of pyruvate in glucose perfusions is consistent with this interpretation. In hearts perfused with glucose and insulin approx. 80% of the 0,2 consumed may be utilized by oxidation of glucose, and this presumably explains why dichloroacetate has only small effects on glucose oxidation under these conditions . Whitehouse & Randle (1973) observed that dichloroacetate perfusion in rat heart substantially increases the activity of pyruvate dehydrogenase measured in extracts of the tissue. They concluded that this activation may result from the conversion of inactive (phosphorylated) pyruvate dehydrogenase into an active form. In glucose perfusions tberefore dichloroacetate may activate pyruvate dehydrogenase and accelerate pyruvate oxidation, leading to accumulations of acetyl-CoA and acetylcarnitine. The increased concentration of acetyl-CoA may result in an increased rate offlow in the tricarboxylate cycle span from acetyl-CoA to glutamate, leading to accumulation of glutamate and consumption of oxaloacetate formed by malgte dpebydrogense and glutamate-aspartate aminotransferase, with concomitant lowering of malate and aspartate concentrations.
Citrate concentration, glycolytic flux and phosphofructokinase activity. The rate of glycolysis was increased by dichloroacetate in rat hearts in acetate perfusions. It is suggested that this is due to lowering of cell citrate concentration with concomitant activation ofphosphofructokinase. Stacpoole & Felts (1971) observed that dichloroacetate lowers citrate concentration in hearts and diaphragms from alloxandiabetic rats and suggested that this may have resulted from inhibition of fatty acid oxidation. Our observations may not be consistent with this interpretation for reasons summarized in the preceding section.
We have been unable to obtain convincing evidence for the mechanism by which dichloroacetate lowers heart citrate concentration in perfusions with acetate and for the failure of dichloroacetate to raise the concentration of citrate in parallel with those of acetylCoA and glutamate in perfusions with glucose. One possibility is a deficiency of oxaloacetate as a result of increased incorporation of oxaloacetate into glutamate and impaired conversion of 2-oxoglutarate into oxaloacetate (suggested by the lower concentrations of aspartate and malate). The lowering of heart pyruvate concentration with dichloroacetate might contribute to oxaloacetate deficiency by restricting transamination between glutamate and pyruvate, which appears to be associated with citrate accumulation during acetate metabolism . Some evidence in support of these possibilities has been obtained in rat hearts perfused with media containing glucose, insulin and 5mM-pyruvate (not shown). Perfusions with pyruvate increased heart citrate concentration and dichloroacetate did not lower citrate concentration with pyruvate. Other possibilities include activation by dichloroacetate of one of the reactions between citrate and glutamate.
Oxidation of acetate, 3-hydroxybutyrate and palmitate. Dichloroacetate inhibits the oxidation of acetate, 3-hydroxybutyrate and palmitate in rat heart and diaphragm muscles. The mechanism of this effect is not known. The common requirement for CoA of pyruvate dehydrogenase, acetyl-CoA synthetase, acyl-CoA synthetases and ,-oxoacyl-CoA thiolases suggests as a possible mechanism competition for CoA between pyruvate dehydrogenase, which is activated by dichloroacetate (Whitehouse & Randle, 1973) , and other enzymes utilizing coenzyme A. Studies with isolated mitochondria may yield evidence on this mechanism.
